On March 4, 2008, GlaxoSmithKline (GSK) announced an addition to warnings on its flu drug Relenza after receiving reports of neuropsychiatric events, like delirium, and abnormal behavior in patients. The association between Relenza and the behaviors, however, has not been established.

The new warnings stem from a U.S. Food and Drug Administration (FDA) advisory panel that reviewed the cases in November 2007.

Source: ?Glaxo adds behavior warning to Relenza flu drug,? Reuters Health, March 4, 2008.2008 (http://www.reuters.com/article/companyNewsAndPR/idUSWBT00853020080304)